Patent · US Active

NK1 antagonists

US8273895B2 · kind B2 · utility

10Cited by

5References

3Claims

0Family size

Assignee

OPKO Health, Inc. · US

Inventors

Sunil Paliwal · Manalapan, US
Gregory A. Reichard · Lovettsville, US
Cheng Wang · Fort Washington, US
Dong Xiao · Hackettstown, US
Hon-Chung Tsui · East Brunswick Township, US
Neng-Yang Shih · Lexington, US
Juan D. Arredondo · Montclair, US
Michelle Laci Wrobleski · Whitehouse Station, US
Anandan Palani · Bound Brook, US

Key dates

Filing date	Dec 14, 2010
Grant date	Sep 25, 2012
Priority date	—
Expiry date	Dec 14, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D513/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A NK1 antagonist having the formula (I),wherein Ar1 and Ar2 are optionally substituted phenyl or heteroaryl, X1 is an ether, thio or imino linkage, R4 and R5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.